Discussant Clifford Hudis, MD, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center, New York, highlighted the obvious clinical advantages of APF530 over the current standard of care. “If this drug were simply the same in price and availability, why wouldn’t you use it? It’s more convenient. It’s a little more effective, and it’s one less thing for all of us in our practice to think about,” he stated.
Dr. Hudis continued: “This indeed is the first and only 5-HT3 receptor antagonist with superiority in a three-drug vs three-drug regimen. It has superior delayed-phase activity. So the question is: What are the next steps for this unapproved agent?” ■
Disclosure: Dr. Hudis reported no potential conflicts of interest.
As part of a three-drug regimen, APF530 (extended-release formulation of granisetron) has become the first 5-HT3 (5-hydroxytryptamine) receptor antagonist to demonstrate superiority over the standard of care for delayed nausea and vomiting after highly emetogenic chemotherapy. According to the...